Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in patients with Cutaneous T-cell Lymphoma.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy